Abivax's ABX464 reduces HIV DNA in CD4+ T cells in Phase IIa

Abivax S.A. (Euronext:ABVX) reported top-line data from 9 HIV-infected patients in the first cohort of the open-label, Spanish Phase IIa ABX464-005 trial showed that once-daily 150 mg oral ABX464 for 28 days plus antiretroviral therapy (ART) significantly reduced median HIV DNA levels in patients’ peripheral blood CD4+ T cells compared to baseline (116 vs. 191 copies/million CD4+ T cells, p<0.01). The company said that "because of low quality and quantity of cells isolated from the rectal biopsies, no reliable HIV DNA data from this tissue were obtained for" the first cohort.

In 2Q18, Abivax expects to report data from the trial’s second cohort, which is evaluating 3 months of treatment with 50 mg ABX464 plus ART in 12 patients...